Original article

Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019

Jacob Romano[a], Jessica Burnside[a], Giada Sebastiani[b], Alnoor Ramji[c], Keyur Patel[d], Mark Swain[e], Sahar Saeed[a,*]

[a] *Public Health Sciences, Queen's University, Kingston, Canada*
[b] *Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Canada*
[c] *Division of Gastroenterology, University of British Columbia, Vancouver, Canada*
[d] *Division of Gastroenterology and Hepatology, University Health Network Toronto, Toronto, Canada*
[e] *Calgary Liver Unit, Cumming School of Medicine, University of Calgary, Canada*

ARTICLE INFO

ABSTRACT

Introduction and Objectives: Prevalence estimates are crucial for enhancing preparedness to prevent and manage chronic diseases. This is the first study to estimate the prevalence of hepatic steatosis and advanced fibrosis in Canada, leveraging a nationally representative survey and multiple validated non-invasive tests (NITs).
Materials and Methods: The Canadian Health Measures Survey (CHMS) is Canada's largest direct health measures survey, which collects data on sociodemographic, clinical factors, and blood chemistry. We determined steatosis using two NITs: the Hepatic Steatosis Index (HSI) and the NAFLD Ridge Score (NRS). The FIB-4 Index and NAFLD fibrosis score (NFS) were used to assess the risk of advanced fibrosis among adults with steatosis. Survey weights were incorporated to account for oversampling, survey nonresponse, and post-stratification.
Results: Between 2009 and 2019, 1365 children (55% males, median age 13 (IQR: 10−15) and 4664 adults (51% males, median age 45 (IQR: 34−62), 57% reporting weekly alcohol consumption) were included in our study. The weighted steatosis prevalence ranged from 9 to 11% among children to 38−48% among adults based on the NRS and HSI, respectively. Between 86−87% of adults with type 2 diabetes and 65−72% with hypertension had evidence of steatosis. Overall, 1.2−2.4% of adults with steatosis were at risk of advanced liver fibrosis.
Conclusions: We estimate between 1 in 3 and 1 in 2 adults have hepatic steatosis, and 195,000−406,200 are at high risk of advanced liver fibrosis in Canada. No routine screening guidelines for liver fibrosis exist in Canada, and most patients are unaware of their condition. Prevalence studies are essential for raising awareness and advocating for the inclusion of steatotic liver disease on national public health agendas.

1. Introduction

The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to be 38.0% (95% confidence interval (CI): 33.7% to 42.5%), with projections indicating incidence is likely to continue to rise [1−3]. The MASLD spectrum begins with hepatic steatosis, which involves fat accumulation within hepatocytes [4]. Over time, these hepatocytes can become injured and inflamed, leading to the development of metabolic dysfunction-associated steatohepatitis (MASH). Approximately 20% of individuals with MASH will progress to hepatic fibrosis [5]. Advanced liver fibrosis is an important prognostic indicator in people with MASH as it places individuals at heightened risk for developing cirrhosis, liver failure, portal hypertension and hepatocellular carcinoma (HCC)

[6−8]. The rise in MASLD prevalence is primarily fueled by the twin obesity and type-2 diabetes mellitus (T2DM) epidemics [9]. Co-morbid metabolic conditions not only increase the likelihood of MASLD but also intensify the risk of a person advancing to severe liver disease and mortality [10]. Data from the United Network of Organ Sharing reveals that MASLD is now the second most common etiology for liver transplantation in the United States [11].

Despite MASLD being a highly prevalent chronic liver disease (CLD) globally, epidemiological data on the sequelae of MASLD is limited in Canada. A recent study evaluating global preparedness to address MASLD as a public health threat found that most countries were unprepared [12]. Canada was no exception, highlighting the need for policies, guidelines, epidemiological data, and enhanced surveillance of MASLD [12]. Except for one modelling study by Swain et al. in 2020, which used obesity/T2DM rates as a proxy to estimate the prevalence of MASLD, there have not been any generalizable prevalence studies of hepatic steatosis and fibrosis in Canada [9].

Canada is a high-income country with an ethnically diverse population. While Canada has a universal health care system, it is segmented between provinces, resulting in differences in services across the country. Estimating the burden of disease is crucial for understanding and improving preparedness to prevent and manage liver disease. In the absence of systematic screening, nationally representative surveys have been used to estimate the prevalence of chronic conditions in the USA and other countries [13,14]. However, unlike other countries, in Canada national surveys do not include routine liver ultrasounds, transient elastography or other imaging technologies, leaving serum-based non-invasive tests (NITs) as the only option to assess liver disease stages. In this study, we leveraged data from the Canadian Health Measures Survey (CHMS), a nationally representative survey across Canada, to estimate the prevalence of hepatic steatosis and advanced fibrosis overall and by sociodemographic subgroups, using validated NITs between 2009 and 2019.

2. Materials and Methods

2.1. Data source

We used the Canadian Health Measures Survey (CHMS), a nationally representative direct health measures survey − the largest of its kind in Canada. The CMHS employs a stratified sampling approach to gather comprehensive information across sexes, age groups, geographical areas, and socioeconomic backgrounds. The objective of this survey is to acquire data for enhancing disease prevention, diagnosis, and treatment while also contributing to the overall improvement of the health and well-being of Canadians [15]. Cross-sectional data on infectious, chronic, and environmental diseases, along with detailed health information, including height, weight, panel blood chemistry, blood pressure, and other metrics, have been collected since 2007 through a combination of physical examinations and interviews [15].

2.2. Study population

Data from cycles 2, 4, and 6 of the CHMS were pooled and analyzed, representing survey collection between 2009 and 2019. Participants aged 9−79 with complete data necessary to calculate the chosen NITs were included in the study. We excluded participants who tested positive for hepatitis B or C virus and human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) to allow for direct comparison with similar studies in the United States.

2.3. Demographic characteristics

Children were defined by age as 9−17 years old. Adults sociodemographic and clinical characteristics obtained during the household survey collection include - age groups (18 to 39, 40 to 64, ≥65), sex, province of residence (Alberta, Atlantic [New Brunswick, Newfoundland and Labrador, Nova Scotia, and P.E.I,], British Columbia, Prairies [Manitoba and Saskatchewan], Ontario, Quebec), race (White, Black, Asian [Filipino, Japanese, Chinese, Korean, South Asian, Southeast Asian], other [Arab, West Asian, Latin American, other racial or cultural origin], not stated), income (<$10,000, $10,001 - $30,000, $30,001 - $65,000, $65,001 -$100,000, $100,001+, not stated), and weekly alcohol intake (0 drinks/week, 1−3 drinks/week, 4−15 drinks/week, 15+ drinks/week). Body mass index (BMI) [weight (kg)/ height (m^2)] and waist circumference (cm) were recorded during physical examination. Self-reported diagnoses of chronic conditions, including T2DM [16], were also recorded. Results from blood chemistry included aspartate aminotransferase (AST, U/L), alanine aminotransferase (ALT, U/L), albumin (g/L), gamma-glutamyltransferase (GGT, U/L), triglycerides (mmol/L), platelet count (10^9/L), white blood cell count (WBC, 10^9/L), hemoglobin A1$_c$ (HbA1c, %), and high-density lipoprotein cholesterol (HDL-C, mmol/l).

2.4. Non-invasive tests to measure the likelihood of hepatic steatosis and advanced fibrosis

The presence of hepatic steatosis and advanced liver fibrosis were each determined using two non-invasive tests (NITs). The following NITs were selected based on comparability to similar studies in other countries as well as those that can be used in future Canadian studies based on availability of the components to calculate the NIT score.

2.4.1. Hepatic steatosis measures

The Hepatic Steatosis Index (HSI) utilizes measurements of ALT, AST, BMI, as well as the presence of T2DM and sex: an HSI value of >36 is associated with the presence of hepatic steatosis and <30 can be used to rule out steatosis. Values that fall between 30 and 36 are considered indeterminate [17]. This non-invasive marker has been used in a number of epidemiological studies[18,19] based on the following formula: [17]

$$HSI = (8 \times (ALT / AST) + BMI + 2(T2DM) + 2(female))$$

The NAFLD Ridge Score (NRS) is a newer NIT that was developed using machine learning methods to identify steatosis with routinely collected serum results as opposed to anthropometric measures. The NRS uses measurements of ALT, HDL-C, TG, HbA1c, WBC, and a binary indicator of hypertension [20]. The NRS employs a dual threshold: individuals with a score <0.24 are considered free from hepatic steatosis, those with a score between 0.24 and 0.44 are categorized as indeterminate, and a score >0.44 signifies the presence of hepatic steatosis [20]. In previous longitudinal and cross-sectional studies, the NRS has been used to detect hepatic steatosis [19,21] based on the following formula:

$$NRS = (-0.614 + (0.007 \ x \ ALT) - (0.214 \ x \ HDL-C) \\ + (0.053 \ x \ TG) + (0.144 \ x \ HbA1c + 0.032 \ x \ WBC) \\ + (0.132 * Hypertension))$$

2.4.2. Advanced fibrosis measures

The FIB-4 index combines age, AST, ALT, and platelet count. A FIB-4 index < 1.3 is categorized as low risk of fibrosis (sensitivity 74 %, specificity 71 %), while a FIB-4 index > 2.67 is categorized as high risk (sensitivity 33 %, specificity 98 %) [22]. Scores between 1.3 and 2.67 are considered indeterminate for advanced fibrosis. The FIB-4 index is currently recommended by most international liver associations as a screening tool for liver fibrosis [23,24]. The FIB-4 is based on the following formula [22]:

$$FIB-4 = Age\ (years)\ x\ AST\ / \left((Platelet\ count)\ x\ \left(ALT^{1/2}\right)\right)$$

The NAFLD Fibrosis Score (NFS) identifies individuals at risk for significant liver fibrosis related to steatosis by utilizing age, BMI, diabetes, AST/ALT ratio, platelet count, and albumin based on the below formula. Scores > 0.676 indicate a high probability of advanced fibrosis (sensitivity 51 %, specificity 98 %), values between −1.455 and 0.676 indicate an indeterminate probability of advanced fibrosis, and < −1.455 suggest a low probability of advanced fibrosis (sensitivity 82 %, specificity 77 %) [25]. The NFS has also been used in epidemiological studies [13,26].

$$NFS = -1.675 + 0.037 \; x \; age \; (years) + 0.094 \; x \; BMI$$
$$+ 1.13 \; x \; diabetes \; (yes = 1, \; no = 2)$$
$$+ 0.99 \; x \; AST/ALT \; ratio - 0.013 \; x \; platelet$$
$$- 0.66 \; x \; albumin$$

2.5. Statistical analysis

We performed a complete case analysis; therefore, participants missing BMI or panel chemistry data necessary to calculate the non-invasive tests, were excluded. Descriptive statistics for categorical variables were reported as a proportion with 95 % confidence intervals (CI) calculated using the logit method. Continuous variables are described as median with 25th and 75th percentiles representing interquartile range (IQR) or mean with 95 % CI. We report the overall prevalence of steatosis in children. Fibrosis status was assessed amongst those who had steatosis based on the HSI. All other predefined subgroups of steatosis and fibrosis prevalence for steatosis and advanced fibrosis were among adults. Survey weights were used to account for the complex survey design, such as oversampling, survey nonresponse, and post-stratification, to ensure that calculated estimates are representative of the Canadian population. We examined the agreement between the NITs using Cohen Kappa statistics by comparing those with and without steatosis (indeterminate excluded) and those with and without fibrosis (excluding indeterminate results). All statistical analyses were conducted using Stata version 17 (Stata Corporation, College Station, TX, USA).

2.6. Ethical statements

The information obtained through the CHMS is subject to the protection provided by the federal Statistics Act. Participation in this survey was voluntary, allowing participants to withdraw from any section of the survey at their discretion. Participants in the survey provided informed written consent [27]. The Health Canada's Research Ethics Board of Canada approved the CHMS in addition to the Office of the Privacy Commissioner of Canada [27]. A thorough security check was required to obtain access to the CHMS and the commitment to signing The Statistics Act Oath or Solemn Affirmation of Office and Secrecy [27]. The study only presents summarized results to maintain privacy and confidentiality, avoiding small cell counts (<15 observations) to protect individual or personal anonymity.

3. Results

3.1. Survey demographics

A total of 17,986 people aged 9 to 79 from cycle 2 (*n* = 6395), cycle 4 (*n* = 5794), and cycle 6 (*n* = 5797) of the CHMS completed the survey. Between 2009 and 2019, after exclusion criteria, 1365 children and 4664 adults were included in this study, representing a national estimate of 37 million people in Canada. Among the children, the median age was 13 (IQR: 10−15), and 55 % were male (95 % CI: 50 −59 %). The median age of the adults was 45 (IQR: 34, 62); 51 % were

male; 75 % self-identified as White, 29 % had a household income of $30,000−65,000/year; 57 % consumed alcohol; 5 % had T2DM; 18 % had hypertension, and there was representation from all the provinces in Canada (Table 1).

3.2. Steatosis prevalence

The adult population identified as having steatosis based on HSI (*n* = 2315) was 53 % male, with a median age of 48 years old, 79 % were white, 32 % had an income of $30,000−65,000, 57 % reported drinking alcohol, 9 % had T2DM, and 24 % had hypertension (Table 2). The overall prevalence of steatosis varied based on the NITs but was high across sociodemographic and clinical factors (Fig. 1& Supplemental Table 1). There was agreement between HSI and NRS, with a kappa statistic of 0.62. Based on the HSI, 2315 adults met the criteria for steatosis, representing 16 million Canadian adults or an overall

Table 1
Characteristics of adults from the CHMS 2009−2019.

	Number of Participants	Weighted % or Mean (95 % CI)
Age (years)	4664	45 (34, 62)
Sex (%)		
Male	2359	51 (48, 53)
Geographical Residence (%)		
Atlantic	543	7 (6, 8)
Quebec	1052	23 (21, 25)
Ontario	1664	40 (37, 43)
Prairies	295	6 (5, 8)
Alberta	426	11 (9, 13)
British Columbia	684	13 (12, 15)
Race (%)		
White	3634	75 (72, 78)
Black	105	2 (2, 4)
Asian	530	13 (11, 15)
Other	251	7 (5, 8)
Missing	144	3 (2, 4)
Income (%)		
≤$10,000	573	12 (10, 14)
$10,001−30,000	1138	25 (22, 27)
$30,001−65,000	1406	29 (27, 32)
$65,001−100,000	679	14 (12, 16)
> $100,000	348	7 (5, 8)
Missing	520	13 (12, 16)
WC (cm)	4664	94.3 (93.9, 94.8)
BMI (kg/m²)	4664	26.9 (26.8, 27.1)
Alcohol Consumption* (%)		
None	1948	43 % (40, 46 %)
1−3	989	22 % (19, 24 %)
4−15	1376	28 % (26, 31 %)
16+	351	7 % (6, 8 %)
Comorbidities (%)		
T2DM	270	5 % (4, 6 %)
Hypertension	797	18 % (16, 20 %)
Panel Chemistry		
AST (U/L)	4664	26.2 (25.8, 26.6)
ALT (U/L)	4664	29.3 (28.9, 29.8)
Albumin (g/L)	4664	43.8 (43.7, 43.9)
GGT (U/L)	4664	29.9 (28.9, 31.0)
HbA1c (%)	4664	5.57 (5.55, 5.60)
HDL-C (mmol/l)	4664	1.4 (1.3, 1.4)
Platelets (10⁹/L)	4664	228 (227, 230)
Triglycerides (mmol/L)	4664	1.4 (1.3, 1.4)
WBC (10⁹/L)	4664	6.3 (6.3, 6.4)

Note:.

* Alcohol consumption is defined as the number of drinks per week.

Abbreviations: CI, Confidence Interval; WC, Waist Circumference; BMI, Body Mass Index [kg/height(m)²]; T2DM, Type 2 Diabetes Mellitus; AST, Aspartate transaminase; ALT, Alanine transaminase; GGT, Gamma-glutamyltransferase; HbA1c; Hemoglobin A1c; HDL-C, High-density lipoprotein cholesterol; WBC, White blood cells.

Table 2
Characteristics of the adult population (*n* = 4664) by HSI and the NRS cut-offs

Characteristics	HSI+(>36) (*n* = 2315) Weighted % or mean (95 % CI)	HSI Indeterminant (*n* = 1754) Weighted % or mean (95 % CI)	HSI- (<30) (*n* = 595) Weighted % or mean (95 % CI)	NRS+ (>0.44) (*n* = 1687) Weighted % or mean (95 % CI)	NRS Indeterminant (*n* = 1692) Weighted % or mean (95 % CI)	NRS- (<0.24) (*n* = 1285) Weighted % or mean (95 % CI)
Sex (%)						
Male	53 (49, 57)	48 (44, 52)	48 (41, 56)	71 (67, 75)	47 (42, 51)	28 (24, 33)
Age (years)	48 (37, 62)	45 (34, 62)	38 (25, 53)	52 (39, 65)	43 (33, 61)	40 (31, 55)
Geographical Residence (%)						
Atlantic	8 (6, 9)	6 (5, 8)	4 (2, 7)	7 (6, 9)	7 (6, 9)	5 (3, 7)
Quebec	25 (22, 28)	21 (18, 25)	21 (16, 27)	23 (19, 27)	23 (19, 26)	23 (19, 28)
Ontario	39 (36, 43)	40 (36, 44)	42 (35, 51)	37 (33, 42)	42 (38, 47)	42 (37, 47)
Prairies	6 (5, 8)	6 (5, 9)	6 (4, 11)	7 (5, 9)	6 (4, 9)	6 (4, 9)
Alberta	11 (8, 14)	12 (9. 15)	8 (5, 13)	14 (10, 18)	10 (8, 14)	8 (6, 11)
British Columbia	11 (9, 13)	15 (12, 18)	19 (13, 26)	12 (10, 15)	12 (9, 15)	16 (13, 21)
Race (%)						
White	79 (76, 83)	73 (69, 77)	62 (54, 70)	75 (71, 79)	75 (72, 80)	74 (68, 78)
Black	3 (1, 5)	2 (1, 4)	2 (1, 6)	2 (1, 5)	2 (1, 3)	4 (2, 6)
Asian	9 (7, 11)	16 (13, 22)	22 (15, 30)	15 (11, 18)	14 (11, 17)	11 (8, 15)
Other	6 (4, 9)	5 (4, 7)	12 (7, 20)	5 (3, 7)	7 (5, 10)	8 (5, 12)
Missing	3 (2, 4)	3 (2, 6)	2 (1, 4)	3 (2, 5)	2 (1, 3)	3 (2, 6)
Income (%)						
≤$10,000	9 (8, 12)	13 (10, 16)	19 (14, 26)	9 (7, 12)	14 (11, 17)	14 (11, 18)
$10,001−30,000	23 (20, 26)	26 (22, 30)	27 (20, 34)	26 (22, 30)	21 (18, 25)	27 (23, 32)
$30,001−65,000	32 (28, 35)	28 (25, 32)	22 (17, 28)	30 (26, 34)	31 (27, 35)	26 (22, 31)
$65,001−100,000	16 (13, 19)	12 (10, 15)	13 (8, 20)	14 (12, 18)	14 (11, 18)	12 (9, 15)
> $100,000	7 (6, 9)	6 (4, 8)	6 (3, 14)	6 (5, 9)	7 (5, 10)	6 (4, 10)
Missing	13 (10, 16)	15 (12, 18)	13 (8, 20)	15 (11, 19)	13 (10, 16)	14 (10, 18)
WC (cm)	104.3 (103.8, 104.9)	87.0 (86.5, 87.4)	77.0 (76.4, 77.6)	103.8 (103.1, 104.5)	92.8 (92.2, 93.5)	83.9 (83.3, 84.5)
BMI (kg/m²)	30.7 (30.5, 30.9)	24.0 (23.9, 24.1)	20.6 (20.5, 20.8)	29.6 (29.3, 29.9)	26.5 (26.3, 26.7)	23.9 (23.7, 24.2)
Alcohol Consumptiogn* (%)						
None	43 (40, 48)	39 (40, 48)	51 (43, 59)	49 (45, 54)	40 (36, 45)	37 (33, 43)
1−3	21 (19, 24)	23 (20, 28)	19 (13, 26)	19 (16, 23)	23 (20, 28)	23 (19, 27)
4−15	29 (26, 31)	31 (27, 35)	23 (18, 29)	24 (20, 28)	31 (27, 35)	33 (29, 38)
15+	7 (6, 8)	7 (5, 9)	7 (4, 12)	8 (6, 11)	6 (4, 8)	7 (5, 9)
Comorbidities (%)						
T2DM	9 (8, 12)			12 (9, 15)		
Hypertension	24 (21, 27)	14 (11, 17)	7 (5, 11)	34 (30, 38)	12 (9, 15)	4 (3, 5)
Panel Chemistry						
AST (U/L)	26.7 (26.3, 27.2)	25.4 (25.0, 25.9)	26. 6 (24.2, 28.9)	31.1 (30.0, 32.1)	24.4 (24.1, 24.8)	22.2 (21.9, 22.6)
ALT (U/L)	34.5 (33.7, 35.2)	25.6 (25.1, 26.0)	20.4 (19.5, 21.3)	39.4 (38.4, 40.3)	26.2 (25.8, 26.6)	20.2 (19.8, 20.6)
Albumin (g/L)	43.3 (43.2, 43.4)	44.0 (43.9, 44.1)	45.1 (44.9, 45.3)	43.7 (43.6, 43.8)	43.6 (43.5, 43.8)	44.2 (44.0, 44.3)
GGT (U/L)	35.9 (34.3, 37.5)	24.7 (23.4, 26.0)	22.0 (18.3, 25.7)	43.6 (41.0, 46.1)	24.7 (23.7, 25.7)	18.9 (18.1, 19.7)
HbA1c (%)	5.7 (5.7, 5.8)	5.4 (5.4, 5.5)	5.3 (5.3, 5.4)	6.0 (5.9, 6.1)	5.4 (5.4, 5.5)	5.2 (5.1, 5.2)
HDL-C (mmol/l)	1.3 (1.2, 1.3)	1.5 (1.4, 1.5)	1.6 (1.6, 1.8)	1.1 (1.1, 1.2)	1.3 (1.3, 1.4)	1.8 (1.7, 1.8)
Platelets (10⁹/L)	230 (228, 233)	226 (223, 229)	225 (221, 230)	231 (228, 235)	227 (225, 230)	225 (222, 228)
Triglycerides (mmol/L)	1.6 (1.6, 1.7)	1.2 (1.1, 1.2)	1.0 (0.9, 1.0)	1.9 (1.9, 2.0)	1.2 (1.1, 1.2)	0.9 (0.8, 0.90)
WBC (10⁹/L)	6.6 (6.5, 6.7)	6.1 (6.0, 6.1)	5.9 (5.7, 6.0)	7.1 (7.0, 7.2)	6.2 (6.1, 6.3)	5.4 (5.3, 5.4)

Note:.
* Alcohol consumption is defined as the number of drinks per week.
Abbreviations: HSI; Hepatic Steatosis Index; NRS, NAFLD Ridge Score; CI, Confidence Interval; WC, Waist Circumference; BMI, Body Mass Index [kg/height(m)²]; T2DM, Type 2 Diabetes Mellitus; AST, Aspartate transaminase; ALT, Alanine transaminase; GGT; Gamma-glutamyltransferase; HbA1c; Hemoglobin A1c; HDL-C, High-density lipoprotein cholesterol; WBC, White blood cells.

prevalence of 48 % (95 % CI: 45−51 %). A total of 1687 adults met the criteria for steatosis, according to the NRS, with an overall prevalence of 38.0 % (95 % CI: 35.0−40.3 %). Overall, the HSI estimated higher prevalence than NRS, particularly for females, 45 % (95 % CI: 42−49 %) compared to 22 % (95 % CI: 19−25 %), respectively. Between 9 % (95 % CI: 7−12 %) and 11 % (95 % CI: 8−15 %) of children had evidence of steatosis, based on the NRS and HSI, respectively and prevalence increased by age groups.

3.3. Fibrosis prevalence

The adult population that was identified as high risk of advanced fibrosis (*n* = 41) based on FIB-4 was 59 % male, with a median age of 68 years old; 65 % reported drinking alcohol, 32 % had T2DM, and 36 % had hypertension (Table 3). Although prevalence of advanced liver fibrosis varied based on the NITs, kappa statistics indicated substantial agreement (kappa: 0.79 between NFS and FIB-4). The overall prevalence of advanced fibrosis was 1.2 % (95 % CI 0.8−1.7 %) based

on FIB-4. Using the NFS, 73 adults were identified as having a high risk of liver fibrosis, representing a prevalence of 2.5 % (95 % CI 1.8 −3.4 %) (Fig. 2 and Table 4). Overall, these estimates represent 195,000−406,200 people across Canada with steatosis who are at high risk of advanced liver disease. The percentage of participants estimated to have an indeterminate probability of having advanced fibrosis varied between 25.0 % using the FIB-4 and 31.5 % using the NFS (Table 3). People with T2DM were more likely to have liver fibrosis compared to those without T2DM (FIB-4: RR 5.8 (95 %CI: 3.1, 10.6) & NFS: RR 27.4, 95 %CI: 16.4, 45.9)). Those with hypertension were also more likely to have liver fibrosis (FIB-4: RR 2.9 (95 %CI: 1.6, 5.3) & NFS: RR 2.9 (95 %CI: 1.8, 4.5)).

4. Discussion

This is the first study to estimate the national prevalence of hepatic steatosis and advanced fibrosis in Canada. We estimate between 1 in 3 and 1 in 2 adults have steatosis based on two

Fig. 1. Steatosis prevalence.The forest plot illustrates the prevalence of steatosis using two non-invasive tests (HSI (blue) and NRS (green)) overall and by subgroups based on socio-demographic and clinical characteristics. This is presented as a proportion from 0 to 1, corresponding to 0 % to 100 %.

validated NITs, of whom 195,000–406,200 Canadians could have advanced liver fibrosis. This study offers a comprehensive analysis of the prevalence of steatosis in subgroups reporting high prevalence across age groups, sex, province, race, income, alcohol consumption, and comorbid conditions. Results suggest that the prevalence of steatosis increases with age and is heightened in males. Furthermore, our data also indicates that when using NITs to evaluate prevalence by sub-groups, the choice of NITs should be evaluated.

Since no representative surveys include transient elastography or liver ultrasounds in Canada, NITs are the only means of estimating generalizable prevalence estimates for hepatic steatosis and fibrosis in the general population. Our study design was similar to other nationally representative studies conducted using blood-based NITs in the US [13,18,28], France [29], Australia [30], Mexico [31], and Korea [32]. The samples studied ranged from 695 [31] to 102,344 participants

[29], and similarly all were cross-sectional by design. The choice of NITs varied based on the available components to calculate various NITs. Six out of seven of these studies excluded people with a history of chronic liver diseases. In the United States, Jones et al., used the National Health and Nutrition Examination Survey (NHANES) and found the overall prevalence of steatosis was 53.5 % in the United States using the HSI, reporting higher rates among males compared to females [18]. Studies among people at higher risk include people with T2DM, where prevalence estimates for steatosis range from 45 % to 85 %, and the prevalence of significant liver fibrosis (based on FIB-4) was 3 %, which aligns with our results [33,34]. A separate recent study using the United States Fatty Liver Index (US-FLI) found the prevalence of steatosis increased with age until 75 years old; 20.4 % (18<45 years), 29.2 % (45-<65 years) 40.6 % (65-<75 years) and 34.8 % (≥75 years) [13]. While we reported the same trend, the prevalence of steatosis

Table 3

Characteristics of the adult population with evidence of steatosis (based on HSI; n = 2315) by FIB-4 and NFS cut-offs.

	FIB-4+ (>2.67)	FIB-4 (1.3−2.66)	FIB-4- (<1.3)	NFS+ (> 0.676) (n = 73)	NFS (−1.455−0.676) (n = 716)	NFS−(< − 1.455) (n = 1526)
	(n = 41)	(n = 580)	(n = 1694)			
Characteristics	Weighted (95 % CI)	Weighted (95 % CI)	Weighted (95 % CI)	Weighted (95 % CI)	Weighted (95 % CI)	Weighted (95 % CI)
Male (%)	59 (40, 76)	60 (54, 66)	51 (46, 56)	52 (37, 68)	54 (47, 60)	53 (48, 58)
Age (years)	68 (66, 71)	63 (63, 64)	44 (43, 44)	66 (64, 68)	61 (61, 62)	42 (42, 43)
WC (cm)	113 (110, 118)	107 (106, 108)	103 (102, 104)	121 (118, 125)	110 (109, 111)	101 (100, 101)
BMI (kg/m²)	32.3 (30.1, 34.5)	30.8 (30.4, 31.2)	30.7 (30.4, 30.9)	37.4 (35.4, 39.3)	32.3 (32.0, 32.7)	29.7 (29.5, 29.9)
Comorbidities (%)						
T2DM	32 (18, 51)	16 (11, 23)	7 (5,9)	77 (63, 86)	21 (16, 28)	1 (1,2)
Hypertension	36 (7, 50)	26 (22, 30)	14 (12, 17)	48 (33, 63)	32 (26, 39)	19 (15, 24)
Alcohol Consumption (%)						
No	35 (23, 49)	49 (34, 47)	44 (41, 48)	44 (30, 59)	43 (38, 48)	45 (40, 49)
Yes*	65 (51, 77)	61 (56, 65)	56 (52, 59)	56 (41, 70)	57 (52, 62)	55 (51, 60)
Panel Chemistry						
AST (U/L)	46.4 (37.8, 55.0)	30.8 (29.7, 31.8)	24.9 (24.5, 25.3)	30.1 (26.1, 34.0)	26.8 (26.1, 27.6)	26.5 (26.0, 27.1)
ALT (U/L)	45.3 (36.4, 54.3)	36.0 (34.4, 37.7)	33.6 (32.8, 34.5)	32.2 (27.5, 36.9)	31.8 (30.8, 32.9)	35.8 (34.8, 36.8)
Albumin (g/L)	41.6 (40.3, 42.8)	43.0 (42.8, 43.3)	43.5 (43.3, 43.6)	41.0 (40.2, 41.8)	42.4 (42.1, 42.6)	43.9 (43.7, 44.0)
GGT (U/L)	102.2 (60.7, 143.7)	40.7 (37.5, 43.9)	32.7 (31.1, 34.3)	60.9 (38.2, 83.5)	37.3 (34.5, 40.1)	34.1 (32.3, 35.9)
HbA1c (%)	6.55 (6.10, 7.00)	5.95 (5.87, 6.03)	5.6 (5.6, 5.7)	6.92 (6.56, 7.30)	6.06 (5.98, 6.14)	5.53 (5.50, 5.57)
HDL-C (mmol/l)	1.29 (1.18, 1.41)	1.30 (1.27, 1.33)	1.24 (1.22, 1.26)	1.17, (1.10, 1.24)	1.24 (1.21, 1.27)	1.27 (1.25, 1.28)
Platelets (10⁹/L)	136 (123, 150)	192 (189, 195)	246.1 (243.5, 248.7)	161 (151, 171)	203 (200, 206)	246.9 (244.1, 249.7)
Triglycerides (mmol/L)	1.70 (1.38, 2.01)	1.72 (1.64, 1.80)	1.6 (1.5, 1.6)	1.90 (1.59, 2.21)	1.70 (1.63, 1.77)	1.58 (1.52, 1.63)
WBC (10⁹/L)	6.6 (5.8, 7.4)	6.3 (6.1, 6.4)	6.7 (6.6, 6.8)	6.8 (6.4, 7.3)	6.5 (6.4, 6.7)	6.7 (6.6, 6.8)

Note: All Data is reported as Mean and 95 % CI, with select subgroups presenting weighted percentage.

  * Yes to alcohol consumption refers to reporting at least one drink per week.

Abbreviations: FIB-4, FIB-4 Index; NFS; NAFLD Fibrosis Score; CI, Confidence Interval; WC, Waist Circumference; BMI, Body Mass Index [kg/height(m)²]; T2DM, Type 2 Diabetes Mellitus; AST, Aspartate transaminase; ALT, Alanine transaminase; GGT, Gamma-glutamyltransferase; HbA1c; Hemoglobin A1c; HDL-C, High-density lipoprotein cholesterol; WBC, White blood cells.

using the NRS and HSI was higher than that of US-FLI. This has been reported elsewhere when all three NITs were compared to each other [21]. Also consistent with other studies we found that prevalence differed by race where Asian people had the lower prevalence compared to people self-identifying as Black or White [13].

The prevalence of steatosis between HSI and NRS differs overall, but the differences by subgroup are not statistically significant except when examining sex. NITs include various demographics, such as age, ethnicity, sex, and clinical indicators that differ by sample populations [35]. NITs such as the USFLI and the FLI do not incorporate comorbid conditions such as T2DM and hypertension into the respective formulas, whereas the HSI and NRS do. Sex is included as an indicator for HSI, which may have prognostic advantages by accounting for the differences in visceral and liver fat accumulation between males and females [36−38]. In addition, the HSI and NFS have overlapping variables (T2DM and BMI). Thus, steatosis defined by HSI may overestimate NFS advanced fibrosis.

We focused our study on the sequela of SLD instead of the prevalence of the different sub-types of SLD (i.e. MASLD, MetALD and ALD)

based on the most recent nomenclature. Interestingly, we found between 24 and 29 % of people with evidence of steatosis could meet the definition of MetALD by drinking 4−14 drinks per week, with an additional 7−8 % by drinking >15 drinks per day. Among people at risk of liver fibrosis, between 56 and 65 % were drinking at least one drink per week when the recommendation for this group of individuals is abstinence.

The data utilized for this study leveraged a national survey representative of the Canadian population, increasing the generalizability of our prevalence estimates, which is the strength of our study. By applying the sampling weights, we could appropriately adjust for complex survey designs, such as oversampling, survey non-response, and post-stratification. Survey weights helped improve our survey estimates' accuracy by ensuring that our conclusions were more representative of the Canadian population. Steatotic liver disease has become a significant liver condition with an impact at the societal level, leading to higher healthcare costs and impairing a patient's health-related quality of life [10,39,40]. Reporting prevalence estimates of steatosis and fibrosis is therefore crucial in guiding policies

Fig. 2. Fibrosis prevalence.The Forest plot illustrates the prevalence of liver fibrosis using two non-invasive tests (FIB-4 (purple) and NFS (red)) overall and by sex and co-morbidities. This is presented as a proportion from 0 to 0.3, corresponding to 0 % to 30 %.

Table 4

Prevalence of steatosis and fibrosis among the adult population in Canada

	Steatosis		Fibrosis	
	HSI + (n = 2315)	NRS + (n = 1687)	FIB-4 + (n = 41)	NFS + (n = 73)
Characteristics	Weighted % (95 % CI)	Weighted % (95 % CI)	Weighted % (95 % CI)	Weighted % (95 % CI)
Overall	48 (45, 51)	38 (35, 40)	1.2 (0.8, 1.7)	2.5 (1.8, 3.4)
Sex				
Male	51 (47, 54)	53 (49, 57)	1 (1, 2)	2 (2, 4)
Female	45 (42, 49)	22 (19, 25)	1 (1, 2)	3 (2, 4)
Comorbidities				
T2DM	87 (80, 92)	86 (79, 91)	4 (2, 8)	20 (1, 29)
Hypertension	65 (58, 70)	72 (66, 77)	2 (1, 3)	5 (3, 8)

Note: HSI+ indicates HSI >36. NRS+ indicates NRS > 0.44. FIB-4+ indicates FIB-4 > 2.67. NFS+ indicates NFS > 0.676.
Abbreviations: HSI; Hepatic Steatosis Index; NRS, NAFLD Ridge Score; FIB-4, FIB-4 Index; NFS; NAFLD Fibrosis Score; CI, Confidence Interval; T2DM, Type 2 Diabetes Mellitus.

and implementing appropriate resource utilization [41−43]. Furthermore prevalence estimates can provide insight into and improve the levels of preparedness to prevent and manage the burden of the spectrum of steatotic liver disease [12]. With the implementation of comprehensive national and subnational guidelines, policymakers and healthcare professionals can effectively allocate resources, including the distribution of health services such as elastography across the country [44,45]. Reporting age and sex-specific prevalence of steatosis and fibrosis is also important to better inform modelling studies and global meta-analysis. While non-invasive tests are not currently considered to be the gold standard for hepatic steatosis and MASH diagnosis, they are readily available, inexpensive, and can be used for epidemiological studies of steatosis and advanced fibrosis prevalence [46,47].

There are several limitations to our study. NITs were used and are known to be imperfect [48]. NITs can yield "indeterminate" scores that range between 30 and 50 % of the study population, posing a significant limitation and requiring secondary diagnostic testing for this population [46,49]. In epidemiological studies, follow-up diagnostic testing is not possible. The incorporation of BMI in HSI may pose challenges in identifying people with lean MASLD or can result in increased prevalence when examining people with elevated BMI, over 40 [47]. Though the FIB-4 index is one of the most utilized NITs in identifying fibrosis, it has lower sensitivity in older individuals, which has led to proposed adjustments to cut-off values [46]. Moreover, poor diagnostic performance among individuals under the age of 35 has been noted for both the FIB-4 index and the NFS [50]. Neither HSI, NRS, NFS, nor FIB-4 index have been validated in children, warranting further validation studies to assess their accuracy [51,52]. The application of the NRS is novel, with limited subsequent validation studies, leaving a gap in the validation o primarily Caucasian populations [53]. However, studies conducted in Sweden [21]. and Italy [19] utilized the NRS in a population that was not predominately Asian, and found high steatosis burden similar to our results. Given that provinces in Canada, such as British Columbia [54] and Ontario [55], have restricted access to AST to liver specialists (hepatologists and gastroenterologists), the NRS allows for an alternative method of estimating the prevalence of hepatic steatosis without using AST in the formula.

The CHMS is a voluntary survey and, therefore, is not immune to the "healthy participants bias," where healthier people are more likely to agree to participate. This is evident in our study since only 5 % of our sample population self-identified as having T2DM despite the Canadian prevalence estimated at 10 %. This difference has been reported elsewhere [56] and may be attributed to the reliance on self-reported data in the CHMS and the younger demographic of our study population. Additionally, we excluded people with HIV/AIDS and hepatitis C and B. Although this is not a requirement for the new definitions of SLD, this allowed us to directly compare our results

with previous studies conducted when definitions of NAFLD required the exclusion of other aetiologies of liver disease. Given very few people met this exclusionary criterion, we don't believe this altered the main results of our study. Finally, certain sub-group analyses (i.e., based on BMI and other co-morbidities) were not possible due to privacy protocols (suppression of small cells) set by Statistics Canada.

5. Conclusions

Currently, no routine screening guidelines for steatotic liver disease exist in Canada, leaving most patients with advanced fibrosis unaware of their condition. This study supports a high prevalence of steatosis in the general population across Canada and confirms people with T2DM are at increased risk of advanced fibrosis. Prevalence studies are essential for raising awareness and advocating for the inclusion of chronic liver disease on national public health agendas.

Declaration of interests

Giada Sebastiani has acted as speaker for Merck, Gilead, Abbvie, Novo Nordisk, Pfizer, served as an advisory board member for Pfizer, Merck, Novo Nordisk, Gilead, and has received unrestricted research funding from Theratecnologies Inc. Mark Swain has served in an advisory role for Ipsen, Novo Nordisk, GSK, Abbott, Advanz, as a speaker for Abbott, and has received clinical trial or research support from Gilead, BMS, CymaBay, Intercept, Genfit, Pfizer, Novartis, Astra Zeneca, GSK, Celgene, Novo Nordisk, Axcella Health Inc., Merck, Galectin Therapeutics, Calliditas Therapeutics, Madrigal, AbbVie, Altimmune, Roche, Kowa, Ipsen, Intercept, 89Bio. Keyur Patel Advisor/Consultant- Novo Nordisk, Merck, Resalis; DSMB- Gilead Sciences, Galectin. Alnoor Ramji has acted as an advisor /consultant for Abbvie, Gilead, Intercept/ Advanz, Janssen, Novo-Nordisc, Pfizer and has grant/research support from Abbvie, Galmed, Gilead, Intercept, Janssen, Merck, Novartis, Novo-Nordisk. Sahar Saeed has served as an advisory board member for Novo Nordisk.

acknowledge all of the CHMS staff, whose collective efforts led to the successful survey launch in March 2007. We would also like to thank the Queen's Research Data Center staff, including Christopher Russel, Yasmine Amirkhakhali, and Jing Liang. Duy Dihn, for his careful review of the manuscript.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.aohep.2024.101757.

References

[1] Lee ECZ, Anand VV, Razavi AC, Alebna PL, Muthiah MD, Siddiqui MS, et al. The global epidemic of metabolic fatty liver disease. Curr Cardiol Rep 2024;26(4):199–210. https://doi.org/10.1007/s11886-024-02025-6.

[2] Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7(9):851–61. https://doi.org/10.1016/s2468-1253(22)00165-0.

[3] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77(4):1335–47. https://doi.org/10.1097/HEP.0000000000000004.

[4] Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. Gastroenterol Hepatol (N Y) 2015;11(3):167–75 https://www.ncbi.nlm.nih.gov/pubmed/27099587.

[5] Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55(3):403–8. https://doi.org/10.1136/gut.2005.069153.

[6] Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115(2):209–18. https://doi.org/10.1172/JCI24282.

[7] Nakai M, Yamamoto Y, Baba M, Suda G, Kubo A, Tokuchi Y, et al. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. Sci Rep 2022;12(1):1449. https://doi.org/10.1038/s41598-022-05492-5.

[8] Schrecker C, Schulze F, Trojan J, Bechstein WO, Zeuzem S, Koch C. Diagnostic performance of non-invasive liver fibrosis scores in patients with early-intermediate hepatocellular carcinoma. J Cancer Res Clin Oncol 2024;150(4):187. https://doi.org/10.1007/s00432-024-05708-3.

[9] Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, et al. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8(2):E429–e36. https://doi.org/10.9778/cmajo.20190212.

[10] Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr 2023;32(3):197–213. https://doi.org/10.7570/jomes23052.

[11] Battistella S, D'Arcangelo F, Grasso M, Zanetto A, Gambato M, Germani G, et al. Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management. Clin Mol Hepatol 2023;29(Suppl):S286–301. https://doi.org/10.3350/cmh.2022.0392.

[12] Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol 2022;76(4):771–80. https://doi.org/10.1016/j.jhep.2021.10.025.

[13] Wang T, Xi Y, Raji A, Crutchlow M, Fernandes G, Engel SS, et al. Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: an updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018. Ann Hepatol 2024;29(1):101154. https://doi.org/10.1016/j.aohep.2023.101154.

[14] Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 2024;79(3):666–73. https://doi.org/10.1097/hep.0000000000000604.

[15] Statistics Canada. Canadian health measures survey (CHMS). Statistics Canada; 2024 https://www.statcan.gc.ca/en/survey/household/5071 Updated June 20Accessed November 28, 2023.

[16] Rosella LC, Lebenbaum M, Fitzpatrick T, Zuk A, Booth GL. Prevalence of prediabetes and undiagnosed diabetes in Canada (2007-2011) according to fasting plasma glucose and HbA1c screening criteria. Diabet Care 2015;38(7):1299–305. https://doi.org/10.2337/dc14-2474.

[17] Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42(7):503–8. https://doi.org/10.1016/j.dld.2009.08.002.

[18] Jones GS, Alvarez CS, Graubard BI, McGlynn KA. Agreement between the prevalence of nonalcoholic fatty liver disease determined by transient elastography and fatty liver indices. Clin Gastroenterol Hepatol 2022;20(1):227–9 e2. https://doi.org/10.1016/j.cgh.2020.11.028.

[19] Ciardullo S, Muraca E, Perra S, Bianconi E, Zerbini F, Oltolini A, et al. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabet Res Care 2020;8(1). https://doi.org/10.1136/bmjdrc-2019-000904.

[20] Yip TC, Ma AJ, Wong VW, Tse YK, Chan HL, Yuen PC, et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. Aliment Pharmacol Ther 2017;46(4):447–56. https://doi.org/10.1111/apt.14172.

[21] Bergram M, Nasr P, Iredahl F, Kechagias S, Rådholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scand J Gastroenterol 2022;57(1):60–9. https://doi.org/10.1080/00365521.2021.1984572.

[22] Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104–12. https://doi.org/10.1016/j.cgh.2009.05.033.

[23] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023;77(5):1797–835. https://doi.org/10.1097/HEP.0000000000000323.

[24] European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.

[25] Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846–54. https://doi.org/10.1002/hep.21496.

[26] Schreiner AD, Livingston S, Zhang J, Gebregziabher M, Marsden J, Koch DG, et al. Identifying patients at risk for fibrosis in a primary care NAFLD cohort. J Clin Gastroenterol 2023;57(1):89–96. https://doi.org/10.1097/MCG.0000000000001585.

[27] Day B, Langlois R, Tremblay M, Knoppers BM. Canadian Health Measures Survey: ethical, legal and social issues. Health Rep 2007;18(Suppl):37–51 https://www.ncbi.nlm.nih.gov/pubmed/18210869.

[28] Kim D, Kim W, Adejumo AC, Cholankeril G, Tighe SP, Wong RJ, et al. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. Hepatol Int 2019;13(2):205–13. https://doi.org/10.1007/s12072-018-09926-z.

[29] Nabi O, Lacombe K, Boursier J, Mathurin P, Zins M, Serfaty L. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. Gastroenterology 2020;159(2):791–3 e2. https://doi.org/10.1053/j.gastro.2020.04.048.

[30] Vaz K, Kemp W, Majeed A, Lubel J, Magliano DJ, Glenister KM, et al. Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle. J Gastroenterol Hepatol 2023;38(10):1823–31. https://doi.org/10.1111/jgh.16314.

[31] García-Compeán D, Villarreal-Pérez JZ, Cavazos MEO, Lavalle-Gonzalez FJ, Borjas-Almaguer OD, Del Cueto-Aguilera AN, et al. Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? Ann Hepatol 2020;19(3):258–64. https://doi.org/10.1016/j.aohep.2020.01.003.

[32] Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol 2020;26(2):209–15. https://doi.org/10.3350/cmh.2019.0065.

[33] Fennoun H, Mansouri SE, Tahiri M, Haraj NE, Aziz SE, Hadad F, et al. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. Pan Afr Med J 2020;37:270. https://doi.org/10.11604/pamj.2020.37.270.9087.

[34] Corbin KD, Pittas AG, Desouza C, Grdinovac KK, Herzig KH, Kashyap SR, et al. Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study. J Diabet Complicat 2023;37(6):108475. https://doi.org/10.1016/j.jdiacomp.2023.108475.

[35] Han AL, Lee HK. Comparison of the diagnostic performance of steatosis indices for discrimination of CT-diagnosed metabolic dysfunction-associated fatty liver disease. Metabolites 2022;12(7). https://doi.org/10.3390/metabo12070664.

[36] Lonardo A, Suzuki A. Nonalcoholic fatty liver disease: does sex matter? Hepatobil Surg Nutr 2019;8(2):164–6. https://doi.org/10.21037/hbsn.2018.12.04.

[37] Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017;34(6):1291–326. https://doi.org/10.1007/s12325-017-0556-1.

[38] Ulbrich EJ, Fischer MA, Manoliu A, Marcon M, Luechinger R, Nanz D, et al. Age- and gender dependent liver fat content in a healthy normal BMI population as quantified by fat-water separating DIXON MR imaging. PLoS One 2015;10(11): e0141691. https://doi.org/10.1371/journal.pone.0141691.

[39] Lazarus JV, Mark HE, Anstee QM, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19(1):60–78. https://doi.org/10.1038/s41575-021-00523-4.

[40] Golabi P, Otgonsuren M, Cable R, Felix S, Koenig A, Sayiner M, et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcome 2016;14:18. https://doi.org/10.1186/s12955-016-0420-z.

[41] Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78(6):1966–86. https://doi.org/10.1097/HEP.0000000000000520.

[42] Lazarus JV, Anstee QM, Hagstrom H, Cusi K, Cortez-Pinto H, Mark HE, et al. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021;18(10):717–29. https://doi.org/10.1038/s41575-021-00477-7.

[43] Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, et al. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol 2023;79(3):618–34. https://doi.org/10.1016/j.jhep.2023.04.035.

[44] Alberta Health Services. Pediatric non-alcoholic fatty liver disease (NAFLD) primary care pathway. Alberta Health ServicesUpdated May; 2024. https://www.albertahealthservices.ca/assets/info/aph/if-aph-scn-dh-pathway-peds-nafld.pdf Accessed November 28, 2023.

[45] Burnside J, Thomas T, Sebastiani G, Saeed S. Geographic disparities in gastroenterologists and transient elastography across Canada. Can Liver J 2023;6(4):417–24.

[46] Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep 2020;2(2):100067. https://doi.org/10.1016/j.jhepr.2020.100067.

[47] Sterling RK, Patel K, Duarte-Rojo A, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology 2024. https://doi.org/10.1097/HEP.0000000000000845.

[48] Gosalia D, Ratziu V, Stanicic F, Vukicevic D, Zah V, Gunn N, et al. Accuracy of non-invasive diagnostic tests for the detection of significant and advanced fibrosis stages in nonalcoholic fatty liver disease: a systematic literature review of the US studies. Diagnost (Basel) 2022;12(11). https://doi.org/10.3390/diagnostics12112608.

[49] Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, et al. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol 2020;5:31. https://doi.org/10.21037/tgh.2019.11.14.

[50] McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112(5):740–51. https://doi.org/10.1038/ajg.2016.453.

[51] Draijer LG, van Oosterhout JPM, Vali Y, Zwetsloot S, van der Lee JH, van Etten-Jamaludin FS, et al. Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: a systematic review. Liver Int 2021;41(9):2087–100. https://doi.org/10.1111/liv.14908.

[52] Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN Clinical Practice Guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64(2):319–34. https://doi.org/10.1097/MPG.0000000000001482.

[53] Yip TC, Ma AJ, Yuen PC, Wong GL. Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population - authors' reply. Aliment Pharmacol Ther 2017;46(5):560–1. https://doi.org/10.1111/apt.14234.

[54] Ivica J, Hill S. The potential for reducing AST testing in hospital settings. Clin Biochem 2019;64:57–9. https://doi.org/10.1016/j.clinbiochem.2018.12.003.

[55] Mohammed-Ali Z, Brinc D, Kulasingam V, Selvaratnam R. Defining appropriate utilization of AST testing. Clin Biochem 2020;79:75–7. https://doi.org/10.1016/j.clinbiochem.2020.02.006.

[56] Statistics Canada. Diabetes among canadian adults. Statistics Canada; 2023 https://www.statcan.gc.ca/o1/en/plus/5103-diabetes-among-canadian-adults Published November 29. Accessed July 11, 2024.